T-cell checkpoint antibodies have revolutionized immunotherapy for cancer, including renal cancer. At Providence Cancer Institute, several clinical trials of these novel approaches are now open to patients with renal cancer, including two studies comparing the effectiveness of different combinations of targeted therapies and immunotherapies.
In his lifetime and through his estate, the late Robert W. Franz gave close to $40 million to Providence Portland Medical Foundation. Providence Cancer Institute has been renamed in his honor.
Learn more about breast cancer screening and the importance of mammograms, featuring Dr. Anupama Acheson from Providence Cancer Institute.
A first-of-its-kind clinical study may offer new hope to patients battling rectal cancer.
The Phase 2 study, newly underway at Providence Cancer...
Patients with hormone-receptor-positive, HER2-positive metastatic breast cancer may qualify for a newly opened clinical trial at Providence Cancer...
Two new studies of investigational and FDA-approved immunotherapies for advanced melanoma are opening soon at Providence Cancer Institute.
With the release of her book Patient 71, Australia native Julie Randall has given cancer patients across the globe hope for life after cancer. Her remarkable story of overcoming stage IV metastatic melanoma was featured in a segment by 60 Minutes Australia chronicling her shocking diagnosis, promise to her family and determination to become “Patient 71” in an immunotherapy clinical trial at Providence Cancer Institute.
Known as "Patient 71," persistence paid off for Australian cancer patient Julie Randall
Learn more about her story ›
She now devotes her...
Two studies at Providence Cancer Institute are focusing on patients’ genomes to help identify the most effective targeted anti-cancer therapies.